Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 18/20 | 0.58 |
| ▸ | XIAP | P98170 | 16/20 | 0.58 |
| ▸ | BIRC3 | Q13489 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL728740 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL12568679 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL2731495 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL2731493 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL2731933 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL18494147 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL19309145 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL20231032 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL20334443 | 1.00 | BIRC2 (0.58) | BIRC2XIAPBIRC3 | |
| SCHEMBL10127375 | 0.99 | BIRC2 (0.59) | BIRC2XIAPBIRC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4493581-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER, METHODS AND SYSTEMS OF DELIVERY THEREOF | University of Rochester (US) | 2025-01-22 | — | — | EP | claimed |
| WO-2023177954-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER, METHODS AND SYSTEMS OF DELIVERY THEREOF | UNIVERSITY OF ROCHESTER (US) | 2023-09-21 | — | — | WO | claimed |
| US-12478601-B2 | Dietary product devoid of at least two non essential amino acids | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-11-25 | — | — | US | disclosed |
| US-20250352549-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2025-11-20 | — | — | US | disclosed |
| US-20250326754-A1 | DNA-PK Inhibitor Compounds and Uses Thereof | ADMARE THERAPEUTICS SOC (CA) | 2025-10-23 | — | — | US | disclosed |
| EP-4634192-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2025-10-22 | — | — | EP | disclosed |
| US-20250296930-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-3151920-B1 | USE OF INHIBITOR OF APOPTOSIS PROTEIN (IAP) ANTAGONISTS IN HIV THERAPY | SANFORD BURNHAM MED RES INST (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4581011-A1 | NOVEL SELECTIVE INHIBITORS OF LYSYL OXIDASES | Syntara Limited (AU) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024128741-A9 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2025-05-30 | — | — | WO | disclosed |
| CN-119968356-A | Novel lysyl oxidase selective inhibitors | 辛塔拉有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20090099103-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG. (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20090005411-A1 | Combinations of Organic Compounds | NOVARTIC AG | 2009-01-01 | — | — | US | disclosed |
| US-20090005411-A1 | Combinations of Organic Compounds | NOVARTIC AG | 2009-01-01 | — | — | US | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| WO-2007115289-A2 | COMBINATIONS COMPRISING BCR-ABL/C-KIT/PDGF-R TK INHIBITORS FOR TREATING CANCER | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007075525-A2 | COMBINATION OF AN IAP-INHIBITOR AND A TAXANE7 | NOVARTIS AG (CH) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296930-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PC | BIRC2 316/4885XIAP 446/4885BIRC3 242/4885 |
| US-20080242658-A1 | Inhibitors of Iap | XIAP, BIRC2, BIRC5 | BIRC2 2/4885XIAP 1/4885BIRC3 5/4885 |
| US-12478601-B2 | Dietary product devoid of at least two non essential amino acids | FABP2, BCAT2, BCAT1 | BIRC2 1955/4885XIAP 1194/4885BIRC3 2727/4885 |
| US-20090005411-A1 | Combinations of Organic Compounds | BIRC5, BIRC3, XIAP | BIRC2 4/4885XIAP 3/4885BIRC3 2/4885 |
| US-20090099103-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | EGFR, ERBB3, ESRRB | BIRC2 512/4885XIAP 174/4885BIRC3 370/4885 |
| US-20250352549-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | MAST1, MAST3, MAST4 | BIRC2 1133/4885XIAP 396/4885BIRC3 880/4885 |
| US-20250326754-A1 | DNA-PK Inhibitor Compounds and Uses Thereof | DCK, CHEK1, CHEK2 | BIRC2 2538/4885XIAP 1543/4885BIRC3 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.